Marseille-Kliniken AG

EANS-News: Marseille-Kliniken AG again reports increased earnings

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
9-month report

Subtitle: - EBIT expanded by more than 75 percent to EUR 7.2 million against
previous year
- Revenue increased to EUR 145.5 million
- Occupancy rate once again strengthened to 88.7 percent
- Redemption of notes realized with a volume of EUR 3.0 million

Hamburg, Germany (euro adhoc) - 9 May 2012 - Marseille-Kliniken AG could
substantially increase its profitability during the first nine months of fiscal
year 2011/2012 (1 July 2011 to 31 March 2012). The repeated gain of the
occupancy rate to 88.7 percent (Q3 2010/2011: 86.8 percent) was a main driver
for the consistent expansion of revenues to EUR 145.5 million (previous year:
EUR 141.6 million). Backed by further savings in administration, EBIT amounted
to EUR 7.2 million, marking a significant increase in earnings against EUR 4.1
million in the previous year. "With this continuing development we are
progressing on profitability improvements according to plan. Additionally it
allowed us to partly finance an early redemption of our notes amounting to EUR
3.0 million.", comments Michael Thanheiser, chairman of Marseille-Kliniken AG.

The company's upward trend, which is visible already since fiscal year
2010/2011, has been made possible by Marseille-Kliniken AG's previously
initiated strategy mix. This includes a focus on care of the elderly, quality
leadership and a decentralised management structure. Moreover a program carried
out to optimise costs also played a role in supporting the company's economic

This progress now continued on all earnings figures with the current quarterly
financial results. Based on an expansion of occupancy rate of 1.9 percentage
points at a sales capacity of 7,949 beds, revenues could again be fostered
against previous year. Nevertheless total costs remained stable with EUR 145.0
million. Therefore despite EBIT also EBITDAR increased by 3.1 percent to EUR
39.8 million (previous year: EUR 38.6 million) and EBITDA by 21.2 percent to EUR
12.0 million (previous year: EUR 9.9 million). Group earnings improved to EUR
4.7 million (previous year EUR 0.0 million). Simultaneously to higher earnings,
also a redemption of own notes with a value of EUR 3.0 million in April 2012
strengthened the company's financial power, as the financing of this measure was
carried out by the successfully generated cash flow as well as by a long term
loan with significant lesser interest payment. Against the backdrop of these
results, Marseille-Kliniken AG is on good track for achieving its future
objectives in both operational excellence and financing.

The complete nine months 2012 financial report such as additional shareholders'
information are available for the public in the investor relations section of
the company's website at

---- End of press release ----

About Marseille-Kliniken AG:

Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57
residential care facilities, three residential units for assisted living and
about 4,700 employees is a market leading listed company on health care in
Germany. The business model is significantly influenced by the demographic
development. Therefore Marseille-Kliniken AG has a secured future. Short-term
economic fluctuations on the other hand exert only a minor influence. As a
consistently modern company with strong focus on quality, the private enterprise
is in a good position within a competitive environment primarily characterized
by regionally active charities.

Further inquiry note:
Hillermann Consulting
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114

end of announcement                               euro adhoc 

company:     Marseille-Kliniken AG
             Alte Jakobstraße 79/80
             D-10179 Berlin
phone:       +49 (0)30 246 32-400
FAX:         +49 (0)30 246 32-401
sector:      Pharmaceuticals
ISIN:        DE0007783003
indexes:     CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
             Hamburg, regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: